RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2
Project

Automation of Biocad industrial complex in the territory Neudorf is complete

Customers: Biocad

Moscow; Pharmaceuticals, Medicine, Healthcare

Product: Complex projects of creation of the engineering systems

Project date: 2018/03  - 2019/03

On April 30, 2019 the Biocad company announced project completion on automation and equipping of Industrial complex No. 2 in the territory of the Neudorf SEZ. The implemented software solution is going to be scaled in future projects of the company including in the territory of Europe, in Finland. Development, implementation and a project startup took one year. The total project investment cost made 6 million dollars.

Industrial complex No. 2

Project objective on automation and hardware of production in biotechnology company BIOCAD is minimization of influence of a human factor on technology process, increase in its reliability, and, as a result, increase in output.

The main complexity of project implementation consisted that the similar equipment is not manufactured in Russia. For technology equipment of the production lines the Russian producers address the European and American vendors that is integrated to a number of the risks including failure to meet time constraints of deliveries, high cost of a software update, and sometimes and failure from deliveries because of sanctions.

Company management it was decided to separate a task into three components:

The software was designed in the company, bioreactors according to own drawings ordered from the Chinese producer Tofflon, processor capacities bought from the developer of the Russian electronics, Fastwel company. In total more than 60 items of equipment with a lump about 30 tons were developed and made.

Thanks to the selected solution of the company it was succeeded to cut by half terms on equipment of industrial complex: at equipment procurement sale of automation systems could take more than 2 years foreign suppliers. When developing own equipment, due to expansion of a circle of contractors, the company managed to reduce costs for start of the plant by 3 times and also it is essential to reduce technology dependence on foreign suppliers.

According to the CEO of BIOCAD company Dmitry Morozov, the basic reason of start of this project is that the foreign developer cannot know technology process of the company as deeply as her specialists.

File:Aquote1.png
We took processor capacities from the Russian company, developed software. Then sent the drawings designed by us to China, and they made to us 'iron'. As a result the equipment customized under us was three times cheaper, than ready IT solutions of the European developers.
Morozov Dmitry, CEO of BIOCAD company
File:Aquote2.png

Started in system operation of automation and technology equipping have a number of additional benefits for BIOCAD:

  • component parts are picked up proceeding from production requirements of the company,
  • all systems are equipped with the digital interface
  • the company received full control over the data which are in the cloud storage.

The maximum information access also allowed to implement the modern technologies, such as bots capable to monitor technology processes on installations in business processes of the company and to timely notify employees on any deviations.

Let's remind that in the middle of 2019 commissioning of the second industrial complex of biotechnology company BIOCAD in the territory of the Neudorf SEZ is expected. In 2019 by the company it was announced increase in project investment cost in the territory of the special economic zone to 23.1 billion rubles. The first plant was constructed by the biotechnology company in 2013 for 560 million rubles. The company was going to invest 3.05 billion rubles and to organize production of biological substances and ready dosage forms until the end of 2019. Now construction expenses of the second industrial complex are increased to 3.72 billion rubles. Additional investments belong to the most expensive construction expenses of laboratories and Research and Development.